|
Synonyms: AV380
Compound class:
Antibody
Comment: Rilogrotug (AV-380; AVEO Pharmaceuticals) is a humanized anti-growth differentiation factor 15 (GDF15) IgG1κ monoclonal antibody. Blocking GDF15 binding to its receptor GFRAL is recognised to induce anti-cachexia efficacy in preclinical models and is proposed as a therapeutic modality to treat cachexia that is caused by over-expression of GDF15 (e.g. cancer-associated cachexia) [1,3].
Data in support of clinical efficacy from a phase 2 trial in patients with cancer-associated cachexia who were administered Pfizer's anti-GDF15 monoclonal, ponsegromab, were published in late 2024 [2]. |
| No information available. |
Summary of Clinical Use  |
| Rilogrotug (AV-380) is a clinical candidate with potential to combat cancer cachexia. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05865535 | A Dose Escalation Study of AV-380 in Metastatic Cancer Patients with Cachexia | Phase 1 Interventional | AVEO Pharmaceuticals, Inc. | ||
| NCT04815551 | A Phase 1 Study of AV-380 in Healthy Subjects | Phase 1 Interventional | AVEO Pharmaceuticals, Inc. | ||
